The White House and US Food and Drug Administration are ramping up research on an old anti-malarial drug, currently in short supply and carrying a potentially concerning safety profile, as a possible treatment for coronavirus.
President Trump directed the FDA to consider hydroxychloroquine sulfate, which is marketed by Bayer AG as Plaquenil, along with chloroquine phosphate, as potential treatments for coronavirus
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?